Targeting LAPTM5 enhances AML sensitivity to cytarabine through autophagy inhibition.
Blocking a specific protein makes a key leukemia drug work better in the lab, suggesting a possible combination strategy worth testing in patients.
This study identifies LAPTM5 as a druggable target that enhances AML sensitivity to cytarabine through autophagy inhibition. The finding suggests a potential combination strategy to overcome cytarabine resistance in AML treatment.
What the study was
- Study design
- Preclinical mechanistic study
- Population
- AML
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Cell Death & Disease
Why it surfaced
Preclinical AML drug target with potential clinical translation. Non-human model cap applied.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.